Global Blood Therapeutics (Global Blood Therapeutics) Debt-to-EBITDA : -2.30 (As of Jun. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Global Blood Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $6.1 Mil. Global Blood Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $652.3 Mil. Global Blood Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2022 was $-286.3 Mil. Global Blood Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -2.30.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Global Blood Therapeutics's Debt-to-EBITDA or its related term are showing as below:

GBT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.37 Med: -1.03 Max: -0.58
Current: -2.29

During the past 9 years, the highest Debt-to-EBITDA Ratio of Global Blood Therapeutics was -0.58. The lowest was -2.37. And the median was -1.03.

GBT's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.325 vs GBT: -2.29

Global Blood Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Global Blood Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics Debt-to-EBITDA Chart

Global Blood Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.58

-1.03

-2.37

Global Blood Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.91	-0.88	-2.05	-2.33	-2.30

Competitive Comparison of Global Blood Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Global Blood Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Global Blood Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Global Blood Therapeutics's Debt-to-EBITDA falls into.

Global Blood Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Global Blood Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(5.67	+	653.947)	/	-278.531
	=	-2.37

Global Blood Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6.119	+	652.267)	/	-286.284
	=	-2.30

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.

Global Blood Therapeutics (NAS:GBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Global Blood Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.gbt.com

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Executives

Jeffrey S Farrow	officer: Chief Financial Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo	director	ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik	officer: Chief Human Resources Officer	6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink	officer: Chief Human Resources Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers	officer: Chief Scientific Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love	director, officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari	officer: Chief Legal Officer	3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr.	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080